Patents Assigned to Emergent Product Development Seattle, LLC
-
Patent number: 9101609Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: GrantFiled: April 13, 2009Date of Patent: August 11, 2015Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
-
Patent number: 9005612Abstract: The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: GrantFiled: April 20, 2012Date of Patent: April 14, 2015Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
-
Patent number: 8853366Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: GrantFiled: February 14, 2012Date of Patent: October 7, 2014Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20140154250Abstract: The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins.Type: ApplicationFiled: March 15, 2013Publication date: June 5, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
-
Publication number: 20140154252Abstract: Variations on the structural themes for multivalent binding molecules with effector function, or scorpions, will be apparent to those of skill in the art upon review of the present disclosure, and such variant structures are within the scope of the invention.Type: ApplicationFiled: March 15, 2013Publication date: June 5, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
-
Publication number: 20140141022Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140127203Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 8, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140072562Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicant: Emergent Product Development Seattle, LLCInventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Patent number: 8632774Abstract: A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.Type: GrantFiled: July 2, 2009Date of Patent: January 21, 2014Assignee: Emergent Product Development Seattle, LLCInventors: Lynda Misher, Alan Keith Lofquist, Peter Robert Baum, Peter Armstrong Thompson
-
Publication number: 20130336977Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: May 31, 2013Publication date: December 19, 2013Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventor: Emergent Product Development Seattle, LLC
-
Publication number: 20130195850Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: ApplicationFiled: November 15, 2012Publication date: August 1, 2013Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: Philip TAN, Sandy Alexander SIMON, Charles G. CERVENY, Christy Anne NILSSON, William BRADY, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Peter Armstrong THOMPSON, Cecile MORALES
-
Publication number: 20130189261Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.Type: ApplicationFiled: March 14, 2013Publication date: July 25, 2013Applicant: Emergent Product Development Seattle, LLCInventor: Emergent Product Development Seattle, LLC
-
Publication number: 20130142793Abstract: The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: April 20, 2012Publication date: June 6, 2013Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: Jeffrey A. LEDBETTER, Martha S. Hayden-Ledbetter
-
Publication number: 20130129723Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: May 23, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan
-
Publication number: 20130095097Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: April 18, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan
-
Publication number: 20130089554Abstract: This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders.Type: ApplicationFiled: December 29, 2010Publication date: April 11, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan, Sateesh Kumar Natarajan, Paul A. Algate, Ruth A. Chenault
-
Patent number: 8409577Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: GrantFiled: June 12, 2007Date of Patent: April 2, 2013Assignee: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Publication number: 20130052195Abstract: The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-? antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.Type: ApplicationFiled: December 23, 2010Publication date: February 28, 2013Applicant: Emergent Product Development Seattle,LLCInventors: Lynda E. Misher, Alan Keith Lofquist
-
Patent number: 8383106Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.Type: GrantFiled: October 21, 2010Date of Patent: February 26, 2013Assignee: Emergent Product Development Seattle, LLCInventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum
-
Patent number: 8333966Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: GrantFiled: April 11, 2009Date of Patent: December 18, 2012Assignee: Emergent Product Development Seattle, LLCInventors: Philip Tan, Sandy Alexander Simon, William Brady, Cecile Morales